Schonhofen, Patrícia http://orcid.org/0000-0001-9551-5012
Bristot, Ivi Juliana
Crippa, José Alexandre
Hallak, Jaime Eduardo Cecílio
Zuardi, Antônio Waldo
Parsons, Richard B.
Klamt, Fábio
Funding for this research was provided by:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (26/2014)
Article History
First Online: 14 August 2018
Compliance with Ethical Standards
:
: This review was supported by the Brazilian funds CNPq/MS/SCTIE/DECIT <i>Pesquisas Sobre Doenças Neurodegenerativas</i> (466989/2014-8), CNPq/MS/SCTIE/DECIT N<sup>∘</sup> 26/2014 – <i>Pesquisas sobre Distúrbios Neuropsiquiátricos</i> (466805/2014-4) and INCT-TM/CNPq/FAPESP (465458/2014-9). AWZ, JECH, FK and JAC are recipients of fellowship awards from <i>Conselho Nacional de Desenvolvimento Científico e Tecnológico</i> (CNPq, Brazil).
: AWZ, JECH and JAC are co-inventors of the patent “Fluorinated CBD compounds, compositions and uses thereof. Pub. No.: WO/2014/108899. International Application No.: PCT/IL2014/050023” Def. US no. Reg. 62193296; 29/07/2015; INPI on 19/08/2015 (BR1120150164927). The University of São Paulo has licensed the patent to <i>Phytecs Pharm</i> (USP Resolution No. 15.1.130002.1.1). The University of São Paulo has an agreement with <i>Prati</i>-<i>Donaduzzi</i> (Toledo, Brazil) to “develop a pharmaceutical product containing synthetic cannabidiol and prove its safety and therapeutic efficacy in the treatment of epilepsy, schizophrenia, Parkinson’s disease, and anxiety disorders.” JECH and JAC have received travel support from and are medical advisors of BSPG-Pharm. AWZ is medical advisor of BSPG-Pharm. PS, FK, IJB, RBP declare no conflics of interest.